Haemonetics Corporation (HAE)

In the past six months, Haemonetics' stock has been impacted by several events. On February 5, 2026, Haemonetics announced its third-quarter fiscal 2026 earnings, reporting $1.31 adjusted EPS, which beat analysts' consensus estimates; however, the stock fell despite beating estimates, possibly due to investor concerns over a year-over-year revenue decrease. The company raised its full-year fiscal 2026 adjusted EPS guidance to $4.90-$5.00. In Q2 2025, the stock dropped 24% despite the company reporting revenue that beat Wall Street's estimates. Over the past year, Haemonetics has experienced a -0.61% change, with its 52-week trading range between $47.32 and $87.32.

Demand for Haemonetics' products and services, particularly in the plasma segment, can exhibit seasonality. However, the company has recently observed an uptick above seasonality of demand in collection volume, with double-digit growth in both the US and internationally. International plasma demand is a strong driver and is expected to more than offset ongoing portfolio rationalization. Product revenue is consistently driven by the demand for disposable blood component collection and processing sets and the associated equipment.

Haemonetics Corp. is a global medical technology company focused on providing innovative solutions to improve the quality, effectiveness, and efficiency of care in the healthcare sector. It operates within the medical devices and instruments industry, as well as computer software and blood banking. The company's business is segmented into Plasma, Blood Center, and Hospital, with a primary emphasis on the Plasma and Hospital segments due to their robust growth potential. Major products and solutions include automated plasma collection systems, donor management software, hemostasis management products, vascular closure devices, interventional technologies, blood management technologies, and fiber optic sensor solutions.

Haemonetics has a significant global presence, with offices located in 16 countries and its products marketed in over 50 countries. The company's revenue is generated almost equally from its three major markets: Asia, Europe, and the Americas.

Haemonetics has demonstrated strong financial health with robust revenue performance and revenue growth over the past three years. Haemonetics has expanded its gross margin and improved free cash flow. Strategic acquisitions aim to strengthen its interventional technologies portfolio and expand its offerings. The launch of the heparinase neutralization (HN) cartridge in EMEA and Japan is accelerating account conversions and expanding the company's global hospital presence. The company's mission to improve patient care and reduce healthcare costs also positively impacts its reputation. The company has faced softness in its interventional technologies segment and challenges in vascular closure markets, which led to hospital growth targets being set at the lower end of previous guidance.

Haemonetics Corp. is a publicly traded company with a mixed ownership structure comprising institutional, retail, and individual investors. Institutional investors hold a substantial portion of the company's stock, approximately 64.57% or 39.01% according to different sources. Major institutional shareholders include Angelo Gordon & Co., L.p., BNP Paribas Asset Management Holding S.A., Sei Investments Co, Oppenheimer Asset Management Inc., Stephens Inc /ar/, LPL Financial LLC, Commonwealth Equity Services, Llc, HB Wealth Management, LLC, Wiley Bros.-aintree Capital, Llc, BlackRock and Vanguard.